Effects of gonadotropin-releasing hormone agonists and antagonists on luteal function

Current Opinion in Obstetrics and Gynecology

Volumn 19, Issue 3, 2007, Pages 258-265

  DiLuigi, Andrea J ^a   Nulsen, John C ^a,b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Controlled ovarian hyperstimulation; Gonadotropin releasing hormone agonist; Gonadotropin releasing hormone antagonist; In vitro fertilization; Luteal phase

Indexed keywords

GONADORELIN AGONIST; GONADORELIN ANTAGONIST;

CORPUS LUTEUM; ENDOMETRIUM BIOPSY; FERTILIZATION IN VITRO; GONADOTROPIN BLOOD LEVEL; GONADOTROPIN RELEASE; HUMAN; LUTEAL PHASE; LUTEOLYSIS; MENSTRUAL CYCLE; OOCYTE DONATION; OOCYTE MATURATION; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PREGNANCY OUTCOME; PREGNANCY RATE; PRIORITY JOURNAL; REVIEW;

CHORIONIC GONADOTROPIN; CORPUS LUTEUM; ENDOMETRIUM; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEAL PHASE; LUTEINIZING HORMONE; OOCYTES; OVARIAN HYPERSTIMULATION SYNDROME; PREGNANCY; PREGNANCY RATE;

EID: 34248570807     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3281338874     Document Type: Review

References (68)

1. Loumaye E. The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in vitro fertilization and embryo transfer. Hum Reprod 1990; 5:357-376.
2. Kolibianakis E, Albano C, Kahn J, et al. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril 2003; 79:873-880.
3. Schally A, Baba Y, Nair R. The amino acid sequence of a peptide with growth hormone-releasing activity isolated from porcine hypothalamus. J Biol Chem 1971; 246:6647-6650.
4. Macklon N, Stouffer R, Giudice L, Fauser B. The science behind 25 years of ovarian hyperstimulation for in vitro fertilization. Endocr Rev 2006; 27:170-207. This is a comprehensive review of the scientific basis of current approaches to ovarian stimulation for IVF.
5. Labrie F, Auclair C, Cusan L, et al. Inhibitory effects of treatment with LHRH or its agonists on ovarian receptor levels and function. Adv Exp Med Biol 1979; 112:687-693.
6. Fauser BC, Devroey P. Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertil Steril 2005; 83:1607-1611.
7. Jennings JC, Moreland K, Peterson CM. In vitro fertilization. A review of drug therapy and clinical management. Drugs 1996; 52:313-343.
8. Chetkowski RJ, Kruse LR, Nass TE. Improved pregnancy outcome with the addition of leuprolide acetate to gonadotropins for in vitro fertilization. Fertil Steril 1989; 52:250-255.
9. Hughes EG, Fedorkow DM, Daya S, et al. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril 1992; 58:888-896.
10. Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab 2003; 14:236-242.
11. Tarlatzis BC, Kolibianakis EM. GnRH agonists vs. antagonists. Best Pract Res Clin Obstet Gynaecol 2007; 21:57-65. This paper provides a concise review of GnRH agonists and antagonists, benefits of each, and studies comparing the two.
12. Tavaniotou A, Smitz J, Bourgain C, Devroey P. Ovulation induction disrupts luteal phase function. Ann NY Acad Sci 2001; 943:55-63.
13. Tavaniotou A, Albano C, Smitz J, Devroey P. Impact of ovarian stimulation on corpus luteum function and embryonic implantation. J Reprod Immunol 2002; 55:123-130.
14. Devroey P, Bourgain C, Macklon N, Fauser BC. Reproductive biology and IVF: ovarian stimulation and endometrial receptivity. Trends Endocrinol Metab 2004; 15:84-90.
15. Olivennes F. The use of gonadotropin-releasing hormone antagonist in ovarian stimulation. Clin Obstet Gynecol 2006; 49:12-32. This paper provides a nice review of GnRH antagonist protocols for COH and clinical outcomes.
16. Casper RF, Yen SS. Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor. Science 1979; 205:408-410.
17. Sheehan KL, Casper RF, Yen SS. Luteal phase defects induced by an agonist of luteinizing hormone-releasing factor: a model for fertility control. Science 1982; 215:170-172.
18. Smitz J, Erard P, Camus M, et al. Pituitary gonadotropin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol. Hum Reprod 1992; 7:1225-1229.
19. Herman A, Ron-El R, Golan A, et al. Impaired corpus luteum function and other undesired results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotropin-releasing hormone. Hum Reprod 1992; 7:465-468.
20. Albano C, Grimbizis G, Smitz J, et al. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil Steril 1998; 70:357-359.
21. Beckers N, Macklon N, Eijkemans M, et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 2003; 88:4186-4192.
22. Tavaniotou A, Devroey P. Luteal hormone profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles. Reprod Biomed Online 2006; 13:326-330.
23. Friedler S, Gilboa S, Schachter M, et al. Luteal phase characteristics following GnRH antagonist or agonist treatment - a comparative study. Reprod Biomed Online 2006; 12:27-32.
24. Garcia J, Jones GS, Acosta AA, Wright GL Jr. Corpus luteum function after follicle aspiration for oocyte retrieval. Fertil Steril 1981; 36:565-572.
25. Ragni G, Vegetti W, Baroni E, et al. Comparison of luteal phase profile in gonadotropin stimulated cycles with or without a gonadotropin- releasing hormone antagonist. Hum Reprod 2001; 16:2258-2262.
26. Duffy D, Manzi D, Benadiva C, et al. Impact of leuprolide acetate on luteal phase function in women undergoing controlled ovarian hyperstimulation and intrauterine insemination. Fertil Steril 2006; 85:407-411.
27. Garcia JE, Acosta AA, Hsiu JG, Jones HW Jr. Advanced endometrial maturation after ovulation induction with human menopausal gonadotropin/human chorionic gonadotropin for in vitro fertilization. Fertil Steril 1984; 41:31-35.
28. Van Steirteghem AC, Smitz J, Camus M, et al. The luteal phase after in-vitro fertilization and related procedures. Hum Reprod 1988; 3:161-164.
29. Forman RG, Eychenne B, Nessman C, et al.Assessing the early luteal phase in in vitro fertilization cycles: relationships between plasma steroids, endometrial receptors, and endometrial histology. Fertil Steril 1989; 51:310-316.
30. Benadiva CA, Metzger DA. Superovulation with human menopausal gonadotropins is associated with endometrial gland-stroma dyssynchrony. Fertil Steril 1994; 61:700-704.
31. Kolb BA, Paulson RJ. The luteal phase of cycles utilizing controlled ovarian hyperstimulation and the possible impact of this hyperstimulation on embryo implantation. Am J Obstet Gynecol 1997; 176:1262-1269.
32. Kolibianakis E, Bourgain C, Albano C, et al. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril 2002; 78:1025-1029.
33. Bourgain C, Devroey P. The endometrium in stimulated cycles for IVF. Hum Reprod Update 2003; 9:515-522.
34. Meyer WR, Novotny DB, Fritz MA, et al. Effect of exogenous gonadotropins on endometrial maturation in oocyte donors. Fertil Steril 1999; 71:109-114.
35. Strowitzki T, Germeyer A, Popovici R, von Wolff M. The human endometrium as a fertility-determining factor. Hum Reprod Update 2006; 12:617-630. This is a detailed review of prior research on endometrial cell-surface markers and receptivity, gene expression, endometrial development in COH cycles, therapeutic options for dysfunctional endometrium and future trends.
36. Takeuchi S, Futamura N, Minoura H, Toyoda N. Possible direct effect of gonadotropin releasing hormone on human endometrium and decidua. Life Sci 1998; 62:1187-1194.
37. Lai T, Zhao Y, Shih I, et al. Expression of L-selectin ligands in human endometrium during the implantation window after controlled ovarian hyperstimulation for oocyte donation. Fertil Steril 2006; 85:761-763.
38. Papanikolaou E, Bourgain C, Kolibianakis E, et al. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes. Hum Reprod 2005; 20:1541-1547.
39. Simon C, Oberye J, Bellver J, et al. Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles. Hum Reprod 2005; 20:3318-3327.
40. Macrow P, Li TC, Seif MW, et al. Endometrial structure after superovulation: a prospective controlled study. Fertil Steril 2004; 61:696-699.
41. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Fertil Steril 1950; 1:3-25.
42. De Ziegler D, Romoscanu I, Ventura P, et al. The uterus and in vitro fertilization. Clin Obstet Gynecol 2006; 49:93-116. This is a comprehensive and practical review of endometrial receptivity and physiology, which includes practical tips for maximizing clinical outcomes.
43. Murray MJ, Meyer WR, Zaino RJ, et al. A critical analysis of the accuracy, reproducibility, and clinical utility of histologic endometrial dating in fertile women. Fertil Steril 2004; 81:1333-1343.
44. Coutifaris C, Myers ER, Guzick DS, et al. Histological dating of timed endometrial biopsy tissue is not related to fertility status. Fertil Steril 2004; 82:1264-1272.
45. Achache H, Revel A. Endometrial receptivity markers, the journey to successful implantation. Hum Reprod Update 2006; 12:731-746. This is an excellent and comprehensive review of the mechanisms, molecules, and mediators involved in the complex process of implantation.
46. Genbacev OD, Prakobphol A, Foulk RA, et al. Trophoblast L-selectin-mediated adhesion at the maternal-fetal interface. Science 2003; 299:405-408.
47. Vlahos N, Lipari C, Bankowski B, et al. Effect of luteal-phase support on endometrial L-selectin ligand expression after recombinant follicle-stimulating hormone and ganirelix acetate for in vitro fertilization. J Clin Endocrinol Metab 2006; 91:4043-4049.
48. Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 2004; 81:1-5.
49. Golan A, Ron-El R, Herman A, et al. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989; 44:430-440.
50. Segal S, Casper RF. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in vitro fertilization. Fertil Steril 1992; 57:1254-1258.
51. Olivennes F, Fanchin R, Bouchard P, et al. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH-antagonist. Fertil Steril 1996; 66:151-153.
52. Buckett WM, Bentick B, Shaw RW. Induction of the endogenous gonadotropin surge for oocyte maturation with intra-nasal gonadotrophin-releasing hormone analogue (buserelin): effective minimal dose. Hum Reprod 1998; 13:811-814.
53. Peñarrubia J, Balasch J, Fábregues F, et al. Human chorionic gonadotropin luteal support overcomes luteal phase inadequacy after gonadotropin-releasing hormone agonist-induced ovulation in gonadotropin- stimulated cycles. Hum Reprod 2006; 13:3315-3318.
54. Shalev E, Geslevich Y, Ben-Ami M. Induction of preovulatory luteinizing hormone surge by gonadotrophin-releasing hormone agonist for women at risk for developing the ovarian hyperstimulation syndrome. Hum Reprod 1994; 9:417-419.
55. Itskovitz J, Boldes R, Levron J, et al. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 1991; 56:213-220.
56. Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian hyperstimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report. Hum Reprod 2000; 15:1965-1968.
57. Engmann L, DiLuigi A, Schmidt D, et al. The use of GnRH agonist to induce oocyte maturation after co-treatment with GnRH antagonist in high-risk patients undergoing IVF prevents the risk of OHSS - a prospective randomized controlled study. Fertil Steril 2007; in press.
58. Humaidan P, Ejdrup Bredkjær H, Bungum L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005; 20:1213-1220.
59. Kolibianakis EM, Schultze-Mosgau A, Schroer A, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005; 20:2887-2892.
60. Orvieto R, Rabinson J, Meltzer S, et al. Substituting HCG with GnRH agonist to trigger final follicular maturation: a retrospective comparison of three different ovarian stimulation protocols. Reprod Biomed Online 2006; 13:198-201.
61. Fauser BC, de Jong D, Olivennes F, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002; 87:709-715.
62. Engmann L, Siano L, Schmidt D, et al. GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. Reprod Biomed Online 2006; 13:639-644.
63. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systemic review and meta-analysis. Hum Reprod Update 2006; 12:159-168.
64. Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernandez ER. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril 2006; 86:1682-1687.
65. Tesarik J, Hazout A, Mendoza C. Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod 2004; 19:1176-1180.
66. Pirard C, Donnez J, Loumaye E. GnRH agonist as novel luteal phase support: results of a randomized, parallel group, feasibility study using intranasal buserelin. Hum Reprod 2005; 20:1798-1804.
67. Pirard C, Donnez J, Loumaye E. GnRH agonist as luteal phase support in assisted reproductive technique cycles: results of a pilot study. Hum Reprod 2006; 21:1894-1900.
68. Tesarik J, Hazout A, Mendoza-Tesarik R, et al. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH-agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod 2006; 21:2572-2579.